Natasha S. Anstee

Natasha S. Anstee

Auto-generated profile, based on publicly available information

Natasha S. Anstee

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MMMohsen Malehmir
Mohsen Malehmir
DPDominik Pfister
Dominik Pfister
SGSuchira Gallage
Suchira Gallage
MSMarta Szydlowska
Marta Szydlowska
DIDonato Inverso
Donato Inverso
MHMathias Heikenwälder
Mathias Heikenwälder

31 March 2017 in Cell Death & Differentiation
Verified
Journal Article
Closed access
ECEmma M Carrington
Emma M Carrington
YZYifan Zhan
Yifan Zhan
JBJamie L Brady
Jamie L Brady
JZJian-Guo Zhang
Jian-Guo Zhang
RSRobyn M Sutherland
Robyn M Sutherland
ALAndrew M Lew
Andrew M Lew

20 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
RTRachel Thijssen
Rachel Thijssen
SDSarah T. Diepstraten
Sarah T. Diepstraten
DMDonia Moujalled
Donia Moujalled
ECEdward Chew
Edward Chew
CFChristoffer Flensburg
Christoffer Flensburg
Andrew H WeiAndrew H Wei
Andrew H Wei
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.

9 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
DMDonia M. Moujalled
Donia M. Moujalled
FBFiona C. Brown
Fiona C. Brown
CCChong Chyn Chua
Chong Chyn Chua
MDMichael A. Dengler
Michael A. Dengler
GPGiovanna Pomilio
Giovanna Pomilio
Andrew H WeiAndrew H Wei
Andrew H Wei
Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with intensive chemotherapy in fitter patients with AML. As most patients still develop recurrent disease, improved understanding of relapse mechanisms is needed. We find that 17% of patients relapsing after venetoclax-based therapy for AML have acquired inactivating missense or frameshift/nonsense mutations in the apoptosis effector gene BAX. In contrast, such variants were rare after genotoxic chemotherapy. BAX variants arose within either leukemic or preleukemic compartments, with multiple mutations observed in some patients. In vitro, AML cells with mutated BAX were competitively selected during prolonged exposure to BCL-2 antagonists. In model systems, AML cells rendered deficient for BAX, but not its close relative BAK, displayed resistance to BCL-2 targeting, whereas sensitivity to conventional chemotherapy was variable. Acquired mutations in BAX during venetoclax-based therapy represent a novel mechanism of resistance to BH3-mimetics and a potential barrier to the long-term efficacy of drugs targeting BCL-2 in AML.

3 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MSMarie Sabatier
Marie Sabatier
RBRudy Birsen
Rudy Birsen
LLLaura Lauture
Laura Lauture
SMSarah Mouche
Sarah Mouche
PAPaolo Angelino
Paolo Angelino
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely unknown in cancer. Here, multiomics analyses uncovered a coordinated activation of C/EBPα and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabolism in vivo and in patients with FLT3-mutant acute myeloid leukemia (AML). Mechanistically, C/EBPα regulated the fatty acid synthase (FASN)–stearoyl-CoA desaturase (SCD) axis to promote fatty acid (FA) biosynthesis and desaturation. We further demonstrated that FLT3 or C/EBPα inactivation decreased monounsaturated FA incorporation to membrane phospholipids through SCD downregulation. Consequently, SCD inhibition enhanced susceptibility to lipid redox stress that was exploited by combining FLT3 and glutathione peroxidase 4 inhibition to trigger lipid oxidative stress, enhancing ferroptotic death of FLT3-mutant AML cells. Altogether, our study reveals a C/EBPα function in lipid homeostasis and adaptation to redox stress, and a previously unreported vulnerability of FLT3-mutant AML to ferroptosis with promising therapeutic application. Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox stress downstream mutant-FLT3 signaling, which confers a vulnerability to ferroptosis upon FLT3 inhibition with therapeutic potential in AML. This article is highlighted in the In This Issue feature, p. 1501

1 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
SLSun Loo
Sun Loo
RDRichard Dillon
Richard Dillon
AIAdam Ivey
Adam Ivey
NANatasha S. Anstee
Natasha S. Anstee
JOJad Othman
Jad Othman
Andrew H WeiAndrew H Wei
Andrew H Wei